Overview

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Status:
Enrolling by invitation

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

Phase:

Phase 3

Details

Lead Sponsor:

Arcutis Biotherapeutics, Inc.